advances in hiv treatment: haart and its complications amy v. kindrick, m.d., m.p.h. national...
TRANSCRIPT
![Page 1: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/1.jpg)
Advances In HIV Treatment: HAART And Its Complications
Amy V. Kindrick, M.D., M.P.H.
National HIV/AIDS Clinicians’ Consultation Center
April 26, 2003
![Page 2: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/2.jpg)
Overview
New concepts and strategies in HIV antiretroviral therapy
Long-term toxicities of ARV therapy
New and investigational ARV agents
New strategies for OI management
Common management challenges
![Page 3: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/3.jpg)
![Page 4: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/4.jpg)
![Page 5: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/5.jpg)
![Page 6: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/6.jpg)
![Page 7: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/7.jpg)
![Page 8: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/8.jpg)
![Page 9: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/9.jpg)
Typical CD4 Response to HAART
![Page 10: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/10.jpg)
Challenges of HAART
Complexity
Toxicity
Accessibility
Incomplete efficacy
Viral resistance
![Page 11: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/11.jpg)
What’s a Clinician to Do?
Expanding number of agents adds complexityMinimal clinical experience when drugs released adds toxicity riskShortage of outcomes data adds uncertainty
![Page 12: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/12.jpg)
New ARV Treatment Strategies and Concepts
Adherence to treatment
ARV resistance and resistance testing
Interrupting ARV therapy
Treating primary HIV infection
![Page 13: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/13.jpg)
Adherence
“Drugs don’t work if people don’t take them.”
C. Everett Koop
![Page 14: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/14.jpg)
Reasons for Non-Adherence: Clinician vs Patient Views
0
10
20
30
40
50
60
valu
e, %
No. of doses orpills
Side Effects Meal Instructions Schedulecomplexity
Other
Clinican
Patient
Chesney M. Adherence to antiretroviral therapy. 12th World AIDS Conference, 1998; Geneva. Lecture 281
![Page 15: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/15.jpg)
Viral Suppression And Adherence By Refill Records
0
10
20
30
40
50
60
70
80
90
95-100% 90-95% 80-90% 70-80% < 70%
Adherence, by prescription refill
% A
chie
ving
<50
0 co
pies
/mL
N = 504 pts on HAART
Montessori, V, et al. XII International Conference on AIDS, Durban, South Africa, 2000. Abstract MoPpD1056.
![Page 16: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/16.jpg)
Measuring Adherence: Electronic Bottle Caps
Caps harbor chips that register each time a bottle is opened or closed
MEMScaps, Aardex Corp.
![Page 17: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/17.jpg)
0
20
40
60
80
100
>95 90-95 80–90 70-80 <70
Pat
ient
s w
ith
HIV
RN
A<
400
cop
ies/
mL
, %
PI adherence, % (electronic bottle caps)
Paterson, et al. 6th Conference on Retroviruses and Opportunistic Infections; 1999; Chicago, IL. Abstract 92.
Viral Suppression And Adherence By MEMS
![Page 18: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/18.jpg)
10% adherence difference = 21% reduction in risk of AIDS
Bangsberg D, et al. AIDS. 2001:15:1181
Pro
port
ion
AID
S-F
ree
Months from entry
P = .0012
0 5 10 15 20 25 30
0.00
0.25
0.50
0.75
1.00
AdherenceO 90–100%O 50–89%O 0–49%
Adherence and AIDS-Free Survival
![Page 19: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/19.jpg)
![Page 20: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/20.jpg)
Why Does HAART Fail?
![Page 21: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/21.jpg)
ARV Resistance
![Page 22: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/22.jpg)
What Is Resistance?
Viral replication in the presence of drug pressure
![Page 23: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/23.jpg)
Basic Pharmacology Principles
IC90
IC50
Cmin
Cmax
Time
Drug Level
Dosing Interval
Area of Potential HIV Replication
Dose Dose
![Page 24: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/24.jpg)
How Does Resistance Develop?
High replication and transcription error rates generate mutant HIV variants
Spontaneously generated variants often contain mutations that confer survival advantage in the presence of antiretroviral agents
Poor adherence or suboptimal regimens can lead to resistance and ‘viral breakthrough’
![Page 25: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/25.jpg)
HIV-1 Quasi Species in Untreated and Treated HIV Infection:
Heterogeneity vs. Selection of Resistant Strains
acute chronic AIDS
Time
V. Simon, MD
Pla
sma
vir
em
ia
![Page 26: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/26.jpg)
Development of Drug Resistance
![Page 27: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/27.jpg)
![Page 28: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/28.jpg)
![Page 29: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/29.jpg)
![Page 30: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/30.jpg)
Antiretroviral Resistance Testing
Goals Improve virologic control and immunologic
benefitMinimize exposure to ineffective agents
OptionsGenotypePhenotype “Virtual phenotype”
![Page 31: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/31.jpg)
DefinitionsGenotype Virus nucleotide sequence from which a protein’s
amino acids can be deduced Mutations reported as change in the deduced amino acid
sequence, e.g., Met184Val Specific mutations confer phenotypic resistance The phenotype is always derived from the genotype
Phenotype Relative growth of the virus in the presence
of different drug concentrations Usually reported as the drug concentration that inhibits virus
replication by 50% (IC50), or the fold increase in IC50
![Page 32: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/32.jpg)
Genotype Vs Phenotype
Availability
Turnaround time 2 weeks
Mutations may precede phenotypic resistance
Lower cost
GENOTYPE
Requires expert interpretation
Measures susceptibility indirectly
Insensitive for detecting minor species
Does not assess interactions among mutations
Does not address drug levels
Measures susceptibility directly
Results are easier to interpret
PHENOTYPE
Restricted availability
Turnaround time 2–4 weeks
Insensitive for detecting minor species
Clinically significant cutoff values may not be defined for some drugs
More expensive
Fast results (2 weeks)
Moderate costVIRTUAL
PHENOTYPE
Measures susceptibility indirectly
Insensitive for detecting interactions between mutations
Strengths Weaknesses
![Page 33: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/33.jpg)
HIV Drug Resistance Assays: DHHS Recommendations
Clinical Situation Recommendation/Rationale
Virologic failure during ART
Determine role of resistance in failure or suboptimal viral suppression
Maximize number of active drugs
Acute HIV infection
Assess possibility of drug-resistant HIV transmission
Treat accordingly
Chronic HIV infection prior to treatment initiation
After D/C ART
Plasma HIV RNA <1000 copies/mL
Uncertain prevalence of resistant virus/assays may not detect minor quasispecies
Assays may not detect certain quasi-species in the absence of selective pressure
HIV RNA too low for reliable detection with current assays
Re
com
me
nd
ed
Op
tion
al
No
t G
en
era
lly R
eco
mm
en
de
d
![Page 34: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/34.jpg)
Resistance Testing Factors
CostTimeAccessTechnical limitations Thresholds Partial resistance
Mutations yet to be identified New drugs Different sequence regions for old drugs
Uncertain clinical impact
![Page 35: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/35.jpg)
Complications Of HIV And ARV Therapy
![Page 36: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/36.jpg)
Long-Term Complications of HIV and ARV Therapy
Body habitus changes
Insulin resistance/hyperglycemia/diabetes
Hyperlipidemia
Lactic acidosis
Hepatic steatosis
Osteopenia
Avascular necrosis
![Page 37: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/37.jpg)
Abnormal Fat RedistributionSyndromes Abnormal fat accumulation
Buffalo hump Increased abdominal girth Increased breast size
Peripheral fat wasting “Sunken cheeks” Thin extremities Prominent peripheral musculature and veins
Prevalence unknown (est. 2% to 80%) Increased with duration of HIV infection & ARV tx
Associated with PI and NRTI useMechanism unknown
![Page 38: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/38.jpg)
Fat Redistribution Syndromes
![Page 39: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/39.jpg)
Cervico-dorsal Fat Pad
![Page 40: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/40.jpg)
Central Fat Accumulation
![Page 41: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/41.jpg)
Facial Lipoatrophy
![Page 42: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/42.jpg)
![Page 43: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/43.jpg)
Abnormal Insulin and Glucose Metabolism
Associated with ARVs, especially PIsMechanism unclear ?PI inhibition of glut-4 transporter
Risk factors Older age African American ethnicity
Clinical syndromes Insulin resistance Hyperglycemia Type 2 diabetes
Treat as usual
![Page 44: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/44.jpg)
Hyperlipidemia
Mechanism unknownPrevalenceClinical syndromesHypertriglyceridemiaHypercholesterolemiaMixed
? Impact on CV riskManage per AHA guidelines
![Page 45: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/45.jpg)
Hyperlipidemia Treatment Considerations
Risk of increased insulin resistance with niacin
Increased risk of myopathy and rhabdomyolysis Interactions between ARVs and statins
Prefer pravastatin or atorvastatin Avoid lovastatin and simvastatin
Interactions between statins and fibrates
May respond to ARV change
![Page 46: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/46.jpg)
Lactic Acidosis And Hepatic Steatosis
Class toxicity of NRTIs (Black Box warning)Incidence est. 4/1000 patient-yearsRisk factorsOlder ageFemale genderddI, ddC, or d4T use > 3 monthsddI+d4T in pregnancy
![Page 47: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/47.jpg)
Lactic Acidosis: Clinical Presentation
Acute or subacute onsetVarying symptoms, including Malaise a/o fatigue Abdominal pain Nausea a/o vomiting Anorexia Hepatomegaly Breathlessness
Abnormal laboratory values Elevated serum
lactate Anion gap Transaminitis Low serum
bicarbonate Elevated
amylase/lipase
![Page 48: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/48.jpg)
Management Of Lactic Acidosis
Be alert to symptomsStop ARVs if symptomatic and lactate elevatedMay consider continuing ARVs if Symptoms absent or mild Lactate only minimally elevated (e.g., 2-4 mmol/l) ddI, d4T can be replaced
Anecdotal treatments for mild disease L-carnitine Riboflavin Thiamine
![Page 49: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/49.jpg)
Delayed Onset NRTI Toxicity
Hypothesized due to toxic effects of NRTIs on human mitochondria NRTIs inhibit DNA polymerase γ required for
mDNA synthesis
Clinical syndromes Pancreatitis Myopathy Peripheral neuropathy Bone marrow toxicity
“D” drugs especially implicated
![Page 50: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/50.jpg)
Avascular Necrosis of the Hip
![Page 51: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/51.jpg)
Osteopenia and Avascular Necrosis of the Radial Head
![Page 52: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/52.jpg)
Changing Therapy:Considerations
Recent clinical history and physical examination
Two plasma HIV RNA levels
CD4+ T cell count
Remaining treatment options
Drug failure or drug toxicity?
Medication adherence
Pharmacology & drug interactions
Resistance profile
Patient preference
![Page 53: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/53.jpg)
Should “Failing” HAART Be Stopped?
Better to stay on some ARV regimen than noneResistance mutations may impair viral
“fitness”Specific mutations may enhance response
to specific ARV agentsCD4 count gains may be sustained despite
incomplete viral suppression
Deeks, et al. NEJM 2/15/01
![Page 54: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/54.jpg)
Antiretroviral Therapy: Persistent Uncertainties
When to start
What to start with
When to change
What to change to
When to stop (if ever)
![Page 55: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/55.jpg)
ARV Treatment Interruption
![Page 56: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/56.jpg)
Treatment Interruption Rationale
Enhance HIV-specific immune response In primary infection In chronic infection
Reduce treatment-associated complicationsToxicityCostTreatment fatigue
![Page 57: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/57.jpg)
Treatment Interruption Target Groups
ARV treatment fully suppressiveStarted during acute infectionStarted after infection chronic
ARV treatment not fully suppressive
![Page 58: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/58.jpg)
Structured Treatment Interruptions
![Page 59: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/59.jpg)
Treatment Interruptions: Real Risks And Theoretical BenefitsReal Risks Loss of viral suppression Development of resistance Repopulation of reservoirs Acute antiretroviral
syndrome CD4 cell decline Loss of immune responses Pharmacokinetic issues Increased transmission Disease progression Death
Theoretical Benefits Reduced drug exposure
Minimize resistance Minimize toxicity Maximize tolerability
Reduced costs Increased access to
drugs Improved adherence Better QOL Enhanced immune
function Long-term viral control off
ARVs
![Page 60: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/60.jpg)
Structured Treatment Interruptions: Conclusions
Still experimental
Rapidly evolving field
Stay tuned!
![Page 61: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/61.jpg)
ARVs For Acute HIV Infection
![Page 62: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/62.jpg)
Primary HIV Infection Rash
![Page 63: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/63.jpg)
Primary HIV Infection Oral Ulcers
![Page 64: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/64.jpg)
Natural History of HIV Infection
![Page 65: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/65.jpg)
The Berlin Patient
Lisziewicz J et al. NEJM 1999; 340: 1683-1684.
![Page 66: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/66.jpg)
ARV Therapy for Primary Infection
Pros May prevent immune
system damage May allow control of
viremia without ARVs
Cons No obvious end point Risk of cumulative
ARV toxicity Risk of suboptimal
adherence leading to emergence of resistance
![Page 67: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/67.jpg)
New ARV Agents
![Page 68: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/68.jpg)
New ARV Agents
T-20
Atazanavir
Capravirine
Phos-Amprenavir
Tipranivir
![Page 69: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/69.jpg)
New OI Management Strategies
Stopping primary prophylaxis
Stopping secondary prophylaxis
Immune restoration syndromes
![Page 70: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/70.jpg)
Common Management Challenges
Coinfection with viral hepatitis More rapid hepatitis progression Increased risk of ARV-associated hepatotoxicity Increased risk of toxicity associated with hepatitis
treatment
Pregnancy Tolerability Teratogenicity Metabolic toxicity Transmission
![Page 71: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/71.jpg)
Resources for HIV/AIDS Clinicians
Handbooks Sanford Guide to HIV/AIDS Therapy The Medical Management of HIV Infection
Internet HIV InSite (http://hivinsite.ucsf.edu) Medscape (www.medscape.com) HIV/AIDS Treatment Information Service
(www.hivatis.org) Johns Hopkins (www.hopkins-aids.edu) National HIV/AIDS Clinicians’ Consultation Center
(www.ucsf.edu/hivcntr)
![Page 72: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/72.jpg)
Consultation Services For HIV/AIDS Clinicians
Local expert cliniciansRegional and local AIDS Education and Training CentersNational HIV Telephone Consultation Service (Warmline) (800) 933-3413
National Clinicians’ Post-Exposure Prophylaxis Hotline (PEPline) (888) HIV-4911
![Page 73: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/73.jpg)
National HIV/AIDS Clinicians’ Consultation Center
A Joint Program of UCSF
and San Francisco General Hospital
Supported by HRSA and CDC
http://www.ucsf.edu/[email protected]
PEPLine (888) 448-4911
Warmline (800) 933-3413
![Page 74: Advances In HIV Treatment: HAART And Its Complications Amy V. Kindrick, M.D., M.P.H. National HIV/AIDS Clinicians’ Consultation Center April 26, 2003](https://reader036.vdocuments.mx/reader036/viewer/2022062806/56649d845503460f94a6b81a/html5/thumbnails/74.jpg)